Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from FibroGen ( (FGEN) ) is now available.
On August 29, 2025, FibroGen completed the sale of its subsidiary, FibroGen International (Hong Kong) Ltd., to AstraZeneca Treasury Limited for approximately $220 million. This transaction allowed FibroGen to repay its senior secured term loan facilities with Morgan Stanley Tactical Value for around $81 million and enter into related agreements, including a transition services agreement. The sale marks a significant financial maneuver for FibroGen, impacting its financial statements and positioning within the industry.
The most recent analyst rating on (FGEN) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on FibroGen stock, see the FGEN Stock Forecast page.
Spark’s Take on FGEN Stock
According to Spark, TipRanks’ AI Analyst, FGEN is a Neutral.
FibroGen’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. While technical analysis shows bullish momentum, the stock’s valuation is unattractive due to negative earnings. The positive sentiment from the earnings call, driven by strategic transactions and extended cash runway, provides some optimism but is overshadowed by financial challenges.
To see Spark’s full report on FGEN stock, click here.
More about FibroGen
Average Trading Volume: 58,186
Technical Sentiment Signal: Sell
Current Market Cap: $45.74M
See more data about FGEN stock on TipRanks’ Stock Analysis page.